HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medennium

This article was originally published in The Gray Sheet

Executive Summary

Novartis subsidiary Ciba Vision acquires an initial 10% equity stake in the ophthalmic product start-up. The move gives Ciba exclusive marketing and distribution rights to Medennium's PRL (phakic refractive lens), an intraocular lens designed for implantation into the posterior chamber of the eye to correct hyperopia and myopia. Phase II trials for the PRL are ongoing in the U.S., with Phase III studies slated to begin in early 2001, Ciba says. A CE mark is expected sometime in 2001
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT013697

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel